Dimethyl fumarate
- Generic Name
- Dimethyl fumarate
- Brand Names
- Tecfidera, Skilarence, Dimethyl fumarate Neuraxpharm, Dimethyl fumarate Mylan, Dimethyl fumarate Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C6H8O4
- CAS Number
- 624-49-7
- Unique Ingredient Identifier
- FO2303MNI2
- Background
Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis. The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-...
- Indication
Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- Associated Conditions
- Clinically Isolated Syndrome (CIS), Relapsing Forms of MS, Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS)
- Associated Therapies
- -
Dimethyl Fumarate in Adrenomyeloneuropathy
- Conditions
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Pujol, Aurora, M.D.
- Target Recruit Count
- 40
- Registration Number
- NCT06513533
- Locations
- 🇪🇸
Bellvitge University Hospital, L'Hospitalet De Llobregat, Barcelona, Spain
🇪🇸University Hospital 12 de Octubre, Madrid, Spain
🇪🇸Donostia University Hospital, Donostia, Spain
Dimethyl Fumarate Treatment for Intracranial Unruptured Aneurysms.
- Conditions
- Interventions
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2023-07-25
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05959759
- Locations
- 🇨🇳
Beijing Neurosurgical Institute & Beijing Tiantan Hospital, Beijing, Beijing, China
A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
- Conditions
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 10500
- Registration Number
- NCT05767736
- Locations
- 🇺🇸
Research Site, Cambridge, Massachusetts, United States
A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 60
- Registration Number
- NCT05658484
- Locations
- 🇨🇳
Renji Hospital, Shanghai Jiatong Uni. School of Medicine, Shanghai, China
🇨🇳Xiangya Hospital Central South University, Changsha, China
🇨🇳Nanfang Hospital, Southern Medical University, Guangzhou, China
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- Conditions
- Interventions
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Biogen
- Target Recruit Count
- 908
- Registration Number
- NCT05658497
- Locations
- 🇨🇭
Inselspital, Bern, Switzerland
🇺🇸IQVIA US Office, Durham, North Carolina, United States
🇮🇪St Vincent's University Hospital, Dublin, Ireland
IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study
- Conditions
- Interventions
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Imcyse SA
- Target Recruit Count
- 150
- Registration Number
- NCT05417269
- Locations
- 🇲🇩
Republican Clinical Hospital, ARENSIA Exploratory Medicine, Chisinau, Moldova, Republic of
Combination of the Immune Modulator Dimethyl Fumarate With Intraarterial Treatment in Acute Ischemic Stroke
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Registration Number
- NCT04891497
Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 50
- Registration Number
- NCT04890366
- Locations
- 🇨🇳
Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China
Dimethyl Fumarate for the Treatment of Intracerebral Hemorrhage
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Registration Number
- NCT04890379
- Locations
- 🇨🇳
Xuanwu Hospital, Beijing, Beijing, Beijing, China
Impact of an Immune Modulator Dimethyl Fumarate on Acute Ischemic Stroke
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 2
- Registration Number
- NCT04890353
- Locations
- 🇨🇳
Xuanwu Hospital, Capital Medical University, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.